GT20029 China Phase II Trial For AGA Reached Primary Endpoint
    Research/Science 4/21/2024

    The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
    View this post in the Community β†’

    Similar Community Posts Join

    5 / 215 results

    Related Research

    5 / 5 results